


MDH-244 for the Treatment of Intractable CNS Disease

MDH-244 (*Sphingomonas paucimobilis* EV) is a new class of first-in-class oral therapeutic indicated for intractable CNS diseases, such as Alzheimer's disease (AD), autism spectrum disorder (ASD), epilepsy, and more

MDH-244

- Naïve (natural) EVs from a single **Sphingomonas** strain



Value Propositions

1. **First-in-class:** a new modality drug with a novel mechanism of action (MoA)
2. **Very safe:** a safe soil bacterium *Sphingomonas paucimobilis*-derived EVs
3. **Effective:** a disease-modifying therapy against intractable CNS diseases, including Alzheimer's disease (AD), autism spectrum disorder (ASD), & epilepsy
4. **Convenient administration:** orally-delivered
5. **Affordable:** cost effective production

MDH-244: Key Indications & Development Timeline

Key Indications

- 1) **Alzheimer's disease (AD)**
- 2) **Autism spectrum disorder (ASD)**
- 3) **Epilepsy**
- 4) Parkinson's disease (PD)

Core patents

1. Core patent (1)
 - ✓ PCT (KR2019/015902) application date at 20/Dec/2019
 - ✓ Registered at KR, & pending at > 10 countries (as of July 2022)
2. Core patent (2)
 - ✓ PCT (KR2021/016743) application date at 16/Nov/2021

Development Timeline

